Tag Archives: Antiparkinson Agents/therapeutic use

Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study

Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study. Neuroimage. June 2011;56(3):1463-1468. Publication Date June 2011 How Analyze was Used “The standard object map was applied to the spatially normalised K i maps and the values for specific 18F-dopa uptake in individual…

A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study

Whone AL, Bailey DL, Remy P, Pavese N, Brooks DJ. A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study. J Nucl Med. July 2004;45(7):1135-1145. Full Text – Open Access Publication Date July 2004 How Analyze was Used “The next check was an interactive visual assessment of the appearance of each…

Clinical and [18F] dopa PET findings in early Parkinson’s disease

Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F] dopa PET findings in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. December 1995;59(6):597-600. Full Text – Open Access Publication Date December 1995 How Analyze was Used “Data analysis was performed with ANALYZE (ANALYZE 7.0 …[Robb and Hanson 1991]) image analysis software.” Keywords Antiparkinson Agents/therapeutic use Case-Control…